drugset / Trial / NCT06771596
Nimotuzumab High-risk, Locally Advanced Squamous Cell Carcinoma of the Cervix
Phase 2
Active not recruiting
43 enrolled
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NaSingle-groupOpen-labelTreatment
Summary
The efficacy and safety of nimotuzumab in the treatment of high-risk, locally advanced squamous cell carcinoma of the cervix.
Timeline
- Start
- 2021-05-12
- Primary completion
- 2025-07
- Completion
- 2025-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nimotuzumab | Monoclonal antibody | 400 mg | Intravenous |